27.21MMarket Cap1.10P/E (TTM)
1.8450High1.8200Low1.15KVolume1.8200Open1.8500Pre Close2.11KTurnover0.01%Turnover RatioLossP/E (Static)14.75MShares4.530052wk High0.36P/B18.58MFloat Cap1.570052wk Low--Dividend TTM10.07MShs Float2869.9200Historical High--Div YieldTTM1.35%Amplitude1.5700Historical Low1.8320Avg Price1Lot Size
VYNE Therapeutics Stock Forum
Upcoming Conference Participation
•H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, New York, NY
•Stifel Immunology and Inflammation Virtual Summit, September 17-18, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
Vyne Therapeutics Announces FDA Clearance of Ind Application for Vyn202, a Novel Bd2-Selective Bet Inhibitor
NEWS
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
GlobeNewswire· 5 mins ago
No comment yet